Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Trial Details

NCT ID
NCT04322890
Phase
PHASE2
Sponsor
Hunan Province Tumor Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Osimertinib
  • Alectinib 150 MG
  • Crizotinib 250 MG
  • Savolitinib, Crizotinib.
  • Chemotherapy
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
  • Age ≥ 18 years.
  • Histologically or cytologically confirmed, Stage IV NSCLC.
  • Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →